Abstract Background/Aim: The immune system has a pivotal role in modulating the response
to chemotherapy in breast cancer (BC). However, the immune status during chemotherapy …

Background Recent evidence support that the immune system has both positive and
negative effects on tumorigenesis. Systemic inflammation has been linked to aggressive …

Background Cancer development is among other factors driven by tumor immune escape
and tumor-mediated changes in the immune response. Investigating systemic immune …

Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic
regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its …

Purpose Neutrophils and platelets have been described as tumor-promoting factors, but
lymphocytes have been described as tumor-inhibiting factors. The prognostic values of the …

Identification of the different elements intervening at the tumor microenvironment seems key
to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers …

Monitoring functional competence of immune cell populations in clinical routine represents a
major challenge. We developed a whole-blood assay to monitor functional competence of …

Results Patients with high absolute lymphocyte count (ALC), low neutrophil-to-lymphocyte
ratio (NLR), and high lymphocyte-to-monocyte ratio (LMR) had significantly longer OS (p …

Background Chemotherapy-induced immune suppression has mainly been studied in
patients with advanced cancer, but the influence of chemotherapy on the immune system in …

The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast
cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its …